Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II
Status:
Completed
Trial end date:
2019-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, multi-site, clinical trial is to determine whether intensive
therapy consisting of cholesterol-lowering statin drugs plus apheresis to cleanse the blood
of low-density lipoprotein (LDL) cholesterol is more effective than statin therapy alone in
reducing plaque volume in heart arteries of patients who have already suffered an acute
coronary syndrome (ACS). The study will also investigate whether this intensive approach can
help increase the presence of endothelial progenitor cells (EPC), stem cells that have been
shown to reduce cardiovascular (CV) events in ACS patients. This study has two phases and FDA
approval for phase II has been received and all information has been updated to reflect
PREMIER Phase II.